Mycobacterium tuberculosis IMPDH in complexes with substrates, products and antitubercular compounds

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Makowska Grzyska, Magdalena ^a   Kim, Youngchang ^a,b   Gorla, Suresh Kumar ^c   Wei, Yang ^c   Mandapati, Kavitha ^c   Zhang, Minjia ^c   Maltseva, Natalia ^a   Modi, Gyan ^c   Boshoff, Helena I ^d   Gu, Minyi ^a   Aldrich, Courtney ^e   Cuny, Gregory D ^c,f   Hedstrom, Lizbeth ^c   Joachimiak, Andrzej ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b ARGONNE NATIONAL LABORATORY   (United States)

^c BRANDEIS UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; GUANINE NUCLEOTIDE; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; ISONIAZID; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE; PHTHALAZINONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UREA DERIVATIVE; ENZYME INHIBITOR; PROTEIN BINDING;

ANTIBACTERIAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN TARGETING; STEREOCHEMISTRY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM;

ANTITUBERCULAR AGENTS; BINDING SITES; ENZYME INHIBITORS; IMP DEHYDROGENASE; MYCOBACTERIUM TUBERCULOSIS; NAD; PROTEIN BINDING;

EID: 84947901377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138976     Document Type: Article

References (55)

1. WHO (2014) Global Tuberculosis Report. Geneva: WHO.
2. Mitchison D, Davies G (2012) The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16: 724-732. doi: 10.5588/ijtld.12.0083 PMID: 22613684
3. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855. doi: 10.1038/nrmicro2236 PMID: 19855401
4. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo Fß, Leibler S, et al. (2013) Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science 339: 91-95. doi: 10.1126/science.1229858 PMID: 23288538
5. Ginsberg AM, Spigelman M (2007) Challenges in tuberculosis drug research and development. Nat Med 13: 290-294. PMID: 17342142
6. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375: 1830-1843.
7. Cegielski JP (2010) Extensively Drug-Resistant Tuberculosis: "There must be some kind of way out of here". Clin Infect Dis 50: S195-S200. doi: 10.1086/651491 PMID: 20397948
8. Chakraborty S, Gruber T, Barry CE, Boshoff HI, Rhee KY (2013) Para-Aminosalicylic Acid Acts as an Alternative Substrate of Folate Metabolism in Mycobacterium tuberculosis. Science 339: 88-91. doi: 10.1126/science.1228980 PMID: 23118010
9. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, et al. (2005) A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science 307: 223-227. PMID: 15591164
10. Hedstrom L, Liechti G, Goldberg JB, Gollapalli DR (2011) The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors. Curr Med Chem 18: 1909-1918. PMID: 21517780
11. Warner DF, Evans JC, Mizrahi V (2014) Nucleotide Metabolism and DNA Replication. Microbiology Spectrum 2. doi: 10.1128/microbiolspec.MGM2-0001-2013 PMID: 26104350
12. Zhang Y, Morar M, Ealick SE (2008) Structural Biology of the Purine Biosynthetic Pathway. Cellular and molecular life sciences: CMLS 65: 3699-3724. doi: 10.1007/s00018-008-8295-8 PMID: 18712276
13. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544. PMID: 9634230
14. Usha V, Gurcha SS, Lovering AL, Lloyd AJ, Papaemmanouil A, Reynolds RC, et al. (2011) Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against Mycobacterium tuberculosis. Microbiology 157: 290-299. doi: 10.1099/mic.0.042549-0 PMID: 21081761
15. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84. PMID: 12657046
16. Chen L, Wilson DJ, Xu Y, Aldrich CC, Felczak K, Sham YY, et al. (2010) Triazole-Linked Inhibitors of Inosine Monophosphate Dehydrogenase from Human and Mycobacterium tuberculosis. J Med Chem 53: 4768-4778. doi: 10.1021/jm100424m PMID: 20491506
17. Usha V, Hobrath JV, Gurcha SS, Reynolds RC, Besra GS (2012) Identification of Novel Mt-Guab2 Inhibitor Series Active against M. tuberculosis. PLoS ONE 7: e33886 (33881-33812). doi: 10.1371/journal.pone.0033886 PMID: 22479467
18. Hedstrom L (2009) IMP Dehydrogenase: Structure, Mechanism, and Inhibition. Chem Rev 109: 2903-2928. doi: 10.1021/cr900021w PMID: 19480389
19. Chen L, Pankiewicz Krzysztof W (2007) Recent developments of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discovery Dev 10: 403-412.
20. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM (1999) Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci U S A 96: 3531-3536. PMID: 10097070
21. Makowska-Grzyska M, Kim Y, Maltseva N, Osipiuk J, Gu M, Zhang M, et al. (2015) A novel cofactor binding mode in bacterial IMP dehydrogenases explains inhibitor selectivity. J Biol Chem 290: 5893-5911. doi: 10.1074/jbc.M114.619767 PMID: 25572472
22. Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, et al. (2008) Targeting a Prokaryotic Protein in a Eukaryotic Pathogen: Identification of Lead Compounds against Cryptosporidiosis. Chem Biol 15: 70-77. doi: 10.1016/j.chembiol.2007.12.010 PMID: 18215774
23. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen B (2010) A Screening Pipeline for Antiparasitic Agents Targeting Cryptosporidium Inosine Monophosphate Dehydrogenase. PLoS Negl Trop Dis 4: e794 (791-712). doi: 10.1371/journal.pntd.0000794 PMID: 20706578
24. Maurya SK, Gollapalli DR, Kirubakaran S, Zhang M, Johnson CR, Benjamin NN, et al. (2009) Triazole Inhibitors of Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase. J Med Chem 52: 4623-4630. doi: 10.1021/jm900410u PMID: 19624136
25. Kirubakaran S, Gorla SK, Sharling L, Zhang M, Liu X, Ray SS, et al. (2012) Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett 22: 1985-1988. doi: 10.1016/j.bmcl.2012.01.029 PMID: 22310229
26. Gorla SK, Kavitha M, Zhang M, Liu X, Sharling L, Gollapalli DR, et al. (2012) Selective and Potent Urea Inhibitors of Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase. J Med Chem 55: 7759-7771. doi: 10.1021/jm3007917 PMID: 22950983
27. Gorla SK, Kavitha M, Zhang M, Chin JEW, Liu X, Striepen B, et al. (2013) Optimization of Benzoxazole- Based Inhibitors of Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase. J Med Chem 56: 4028-4043. doi: 10.1021/jm400241j PMID: 23668331
28. Johnson CR, Gorla SK, Kavitha M, Zhang M, Liu X, Striepen B, et al. (2013) Phthalazinone inhibitors of inosine-5′-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett 23: 1004-1007. doi: 10.1016/j.bmcl.2012.12.037 PMID: 23324406
29. Sun Z, Khan J, Makowska-Grzyska M, Zhang M, Cho JH, Suebsuwong C, et al. (2014) Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase (CpIMPDH) Inhibitors. J Med Chem 57: 10544-10550. doi: 10.1021/jm501527z PMID: 25474504
30. MacPherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, Zhang M, et al. (2010) The Structural Basis of Cryptosporidium-Specific IMP Dehydrogenase Inhibitor Selectivity. J Am Chem Soc 132: 1230-1231. doi: 10.1021/ja909947a PMID: 20052976
31. Gollapalli DR, MacPherson IS, Liechti G, Gorla SK, Goldberg JB, Hedstrom L (2010) Structural Determinants of Inhibitor Selectivity in Prokaryotic IMP Dehydrogenases. Chem Biol 17: 1084-1091. doi: 10.1016/j.chembiol.2010.07.014 PMID: 21035731
32. Makowska-Grzyska M, Kim Y, Wu R, Wilton R, Gollapalli DR, Wang XK, et al. (2012) Bacillus anthracis Inosine 5′-Monophosphate Dehydrogenase in Action: The First Bacterial Series of Structures of Phosphate Ion-, Substrate-, and Product-Bound Complexes. Biochemistry 51: 6148-6163. PMID: 22788966
33. Carr SF, Papp E, Wu J, Natsumeda Y (1993) Characterization of Human Type I and Type II IMP Dehydrogenase. J Biol Chem 268: 27286-27290. PMID: 7903306
34. Hager PW, Collart FR, Huberman E, Mitchell BS (1995) Recombinant Human Inosine Monophosphate Dehydrogenase Type I and Type II Proteins. Biochem Pharmacol 49: 1323-1329. PMID: 7763314
35. Mortimer SE, Hedstrom L (2005) Autosomal dominant retinitis pigmentosa mutations in inosine 5′-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem J 390: 41-47. PMID: 15882147
36. Wang W, Hedstrom L (1997) Kinetic Mechanism of Human Inosine 5′-Monophosphate Dehydrogenase Type II: Random Addition of Substrates and Ordered Release of Products. Biochemistry 36: 8479-8483. PMID: 9214292
37. Mandapati K, Gorla SK, House AL, McKenney ES, Rao SN, Gollapalli DR, et al. (2014) Repurposing Cryptosporidium inosine 5′-monophosphate dehydrogenase inhibitors as potential antibacterial agents. ACS Med Chem Lett 5: 846-850. doi: 10.1021/ml500203p PMID: 25147601
38. Gorla SK, McNair NN, Yang G, Gao S, Hu M, Jala VR, et al. (2014) Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother 58: 1603-1614. doi: 10.1128/AAC.02075-13 PMID: 24366728
39. Rejman D, Olesiak M, Chen L, Patterson SE, Wilson D, Jayaram HN, et al. (2006) Novel Methylenephosphophosphonate Analogues of Mycophenolic Adenine Dinucleotide. Inhibition of Inosine Monophosphate Dehydrogenase. J Med Chem 49: 5018-5022. PMID: 16884314
40. Lesiak K, Watanabe KA, Majumdar A, Powell J, Seidman M, Vanderveen K, et al. (1998) Synthesis of a Methylenebis(phosphonate) Analogue of Mycophenolic Adenine Dinucleotide: A Glucuronidation-Resistant MAD Analogue of NAD. J Med Chem 41: 618-622. PMID: 9484510
41. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85: 921-930. PMID: 8681386
42. Prosise GL, Wu JZ, Luecke H (2002) Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site. J Biol Chem 277: 50654-50659. PMID: 12235158
43. Kuppuraj G, Sargsyan K, Hua Y-H, Merrill AR, Lim C (2011) Linking Distinct Conformations of Nicotinamide Adenine Dinucleotide with Protein Fold/Function. J Phys Chem B 115: 7932-7939. doi: 10.1021/jp1118663 PMID: 21612228
44. Prosise GL, Luecke H (2003) Crystal structures of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism. J Mol Biol 326: 517-527. PMID: 12559919
45. Cooney D, Hamel E, Cohen M, Kang GJ, Dalal M, Marquez V (1987) A simple method for the rapid determination of the stereospecificity of NAD-dependent dehydrogenases applied to mammalian IMP dehydrogenase and bacterial NADH peroxidase. Biochim Biophys Acta, Protein Struct Mol Enzymol 916: 89-93.
46. Xiang B, Markham GD (1997) Probing the mechanism of inosine monophosphate dehydrogenase with kinetic isotope effects and NMR determination of the hydride transfer stereospecificity. Arch Biochem Biophys 348: 378-382. PMID: 9434751
47. Voth AR, Khuu P, Oishi K, Ho PS (2009) Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 1: 74-79. doi: 10.1038/nchem.112 PMID: 21378804
48. Bissantz C, Kuhn B, Stahl M (2010) A Medicinal Chemist's Guide to Molecular Interactions. J Med Chem 53: 5061-5084. doi: 10.1021/jm100112j PMID: 20345171
49. Cotton NPJ, White SA, Peake SJ, McSweeney S, Jackson JB (2001) The Crystal Structure of an Asymmetric Complex of the Two Nucleotide Binding Components of Proton-Translocating Transhydrogenase. Structure 9: 165-176. PMID: 11250201
50. Thoden JB, Frey PA, Holden HM (1996) Crystal Structures of the Oxidized and Reduced Forms of UDP-galactose 4-Epimerase Isolated from Escherichia coli. Biochemistry 35: 2557-2566. PMID: 8611559
51. Geiser M, Cèbe R, Drewello D, Schmitz R (2001) Integration of PCR Fragments at any Specific Site within Cloning Vectors without the Use of Restriction Enzymes and DNA Ligase Biotechniques 31: 88-92. PMID: 11464525
52. Kim Y, Babnigg G, Jedrzejczak R, Eschenfeldt WH, Li H, Maltseva N, et al. (2011) High-throughput protein purification and quality assessment for crystallization. Methods 55: 12-28. doi: 10.1016/j.ymeth.2011.07.010 PMID: 21907284
53. Duckworth BP, Wilson DJ, Nelson KM, Boshoff HI, Barry CE, Aldrich CC (2012) Development of a Selective Activity-Based Probe for Adenylating Enzymes: Profiling MbtA Involved in Siderophore Biosynthesis from Mycobacterium tuberculosis. ACS Chem Biol 7: 1653-1658. doi: 10.1021/cb300112x PMID: 22796950
54. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16: 10881-10890. PMID: 2849754
55. Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42: W320-W324. doi: 10.1093/nar/gku316 PMID: 24753421